MAPK8 and central nervous system cancer: In Figure 8A–8L, it was discovered that glioma cells may exhibit resistance to AZD7762, Paclitaxel, Nilotinib, JNK inhibitor VIII, JNK.9L, GSK269962A, Gefitinib, FTI.277, Doctaxel, Cyclopamine, Camptothecin, and Bicalutamide.